Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19-Reference-Cited by-同舟云学术

Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19

Published:2023-04 Issue:4 Volume:176 Page:496-504
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Kip Kevin E.¹,McCreary Erin K.²,Collins Kevin¹,Minnier Tami E.³^ORCID,Snyder Graham M.²^ORCID,Garrard William¹^ORCID,McKibben Jeffrey C.¹,Yealy Donald M.⁴,Seymour Christopher W.⁵,Huang David T.⁶^ORCID,Bariola J. Ryan²,Schmidhofer Mark⁷,Wadas Richard J.⁴^ORCID,Angus Derek C.⁵^ORCID,Kip Paula L.³^ORCID,Marroquin Oscar C.¹

Affiliation:

1. Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (K.E.K., K.C., W.G., J.C.M., O.C.M.)

2. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (E.K.M., G.M.S., J.R.B.)

3. Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (T.E.M., P.L.K.)

4. Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (D.M.Y., R.J.W.)

5. Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (C.W.S., D.C.A.)

6. Department of Emergency Medicine and Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (D.T.H.)

7. Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.S.).

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Reference33 articles.

1. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

2. Monoclonal Antibodies for COVID-19

3. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

4. Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era

5. Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience;International Immunopharmacology;2024-12

2. Clinical practice guideline supported administration of monoclonal antibody therapy for high-risk patients with COVID-19: Experience of a quaternary care centre;Journal of the Association of Medical Microbiology and Infectious Disease Canada;2024-09-10

3. Vitamin D supplementation and calcium: Many-faced gods or nobody in fighting against Corona Virus Disease 2019;Clinical Nutrition ESPEN;2024-08

4. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort;Heliyon;2024-08

5. Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China;Frontiers in Pharmacology;2024-07-22